Items where Author is "Macke, H. R."

2012

Villard, L. and Romer, A. and Marincek, N. and Brunner, P. and Koller, M. T. and Schindler, C. and Ng, Q. K. and Macke, H. R. and Muller-Brand, J. and Rochlitz, C. and Briel, M. and Walter, M. A.. (2012) Cohort study of somatostatin-based radiopeptide therapy with [(90)Y-DOTA]-TOC versus [(90)Y-DOTA]-TOC plus [(177)Lu-DOTA]-TOC in neuroendocrine cancers. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 30, H. 10. pp. 1100-1106.

2011

Imhof, A. and Brunner, P. and Marincek, N. and Briel, M. and Schindler, C. and Rasch, H. and Macke, H. R. and Rochlitz, C. and Muller-Brand J., and Walter, M. A.. (2011) Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 29, H. 17. pp. 2416-2423.

2007

Iten, F. and Muller, B. and Schindler, C. and Rochlitz, C. and Oertli, D. and Macke, H. R. and Muller-Brand, J. and Walter, M. A.. (2007) Response to [90Yttrium-DOTA]-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: a phase II clinical trial. Clinical Cancer Research, 13 (22). pp. 6696-6702.

1999

Andre, J. P. and Toth, E. and Fischer, H. and Seelig, A. and Macke, H. R. and Merbach, A. E.. (1999) High relaxivity for monomeric Gd(DOTA)-based MRI contrast agents, thanks to micellar self-organization. Chemistry, Vol. 5, no. 10. pp. 2977-2983.